Anticoagulants: Therapeutics, risks, and toxicity - Special emphasis on heparin-induced thrombocytopenia (HIT)

Journal of Pharmacy Practice

Volumn 25, Issue 1, 2012, Pages 22-29

  O'Donnell, James ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulants; heparin; HIT; thrombocytopenia; warfarin

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; DANAPAROID; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT; FONDAPARINUX; GLYCOPROTEIN IB; GLYCOSAMINOGLYCAN; HEPARIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; THROMBOXANE A2; VON WILLEBRAND FACTOR; WARFARIN;

ANTIBODY TITER; ANTICOAGULANT THERAPY; AUTOIMMUNITY; BINDING SITE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CONTINUOUS HEMOFILTRATION; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN CLOT; FLUSHING; HEART ASSIST DEVICE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; LAW SUIT; MORBIDITY; MORTALITY; PATHOGENESIS; PATIENT SELECTION; PHARMACIST; PREDICTIVE VALUE; PREGNANT WOMAN; PREVALENCE; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; SEROTONIN RELEASE; STROKE; TACHYCARDIA; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOGENESIS; URINARY EXCRETION; VENOUS STASIS; VENOUS THROMBOEMBOLISM;

EID: 84859530018     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190011431146     Document Type: Review

References (8)

1. (chapter 115 contributor). Antiplatelet, Anticoagulant, and Fibrinolytic Drugs, In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Oongo DL, et al. eds. Harrison's Principles of Internal Medicine, 17e http://www.accessmedicine.com/ content.aspx?aid=2891975
2. Pradaxa [package insert]. www.pradaxa.com (official prescribing information). Ridgefield, CT 06877, USA: Boehringer Ingelheim: 2011.
3. Bradner JE, Eikkelboom JW. Emerging anticoagulants and heparin-induced thrombocytopenia: indirect and direct factor Xa inhibitors and oral thrombin inhibitors Chapter 17, In: Warkentin TE, Greinacher A. Heparin-Induced Thrombocytopenia. 4th ed. New York, NY:Informa Healthcare; 2007: 444.
4. Priziola JL, Smythe MA, Dager WE. Drug-Induced thrombocytopenia in critically ill patients. Drit Care Med. 2010; 38(6 suppl): S145-S154.
5. Warkentin TE. Clinical picture of heparin-induced thrmbocytopenia. Chapter 2, In: Warkentin TE, Greinacher A. eds. Heparin-Induced Thrombocytopenia. 4th ed. New York, NY: Informa Healthcare; 2007: 26.
6. Alban S, Greinqacher A. Role of Sulfated Polysacchariedes in the pathogenesis of heparin-induced thrombocytopenia Chapter 7, In: Warkentin TE, Greinacher A. eds. Heparin-Induced Thrombocytopenia. 4th ed. New York, NY: Informa Healthcare; 2007: 172.
7. Pouplard C, Gueret P, Foussier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2007; 5(7): 1373-1379. (Pubitemid 46965362)
8. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. Chapter 12, In: Warkentin TE, Greinacher A. eds. Heparin-Induced Thrombocytopenia. 4th ed. New York, NY: Informa Healthcare; 2007: 296.